Angelia Thompson, MD
Ophthalmology · Lexington, KYNPI 1427162395
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $10,923 of the $10,970 with a category attached, or 99.6%. US Retina LLC accounts for 99.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $4,655 and has fallen 99.5% since, to $23 in 2024. Among ophthalmology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 7 payments — averaging $1567.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$11K
- Amgen$24
- AbbVie$23
What the payments were for
- Food & beverage$230%
- Education$240%
- Ownership interest$10,923100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 5 | $10,923 |
| Amgen | 1 | $24 |
| AbbVie | 1 | $23 |
How this compares
$10,970 in reported general payments places this provider in the 90th percentile of 216 ophthalmology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 24 | $18,120 |
| Brimonidine Tartrate | 84 | $9,921 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $4,498 |
| Alphagan PBrimonidine Tartrate | 16 | $4,160 |
| Prednisolone Acetate | 85 | $2,398 |
| Latanoprost | 180 | $1,382 |
| ErythromycinErythromycin Base | 115 | $1,285 |
| Difluprednate | 18 | $1,193 |
| Acetazolamide ErAcetazolamide | 16 | $665 |
| Timolol Maleate | 54 | $452 |
| Doxycycline Hyclate | 23 | $322 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $266 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 13 | $90 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Alphagan P | $23 | $26,77757 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 216 ophthalmology providers in Kentucky.
Other ophthalmology in Lexington
- Gary WortzLexington$159K
- Bruce KofflerLexington$49K
- Asim PirachaLexington$17K
- Ryan SmithLexington$12K
- James HuffmanLexington$10K
- Shivani ReddyLexington$8K
- Paras VoraLexington$4K
- Michael TannerLexington$4K
- Edward HollandEdgewood$678K
- Jeremy ClarkLouisville$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.